SAB Biotherapeutics, Inc.SABSNASDAQ
Loading
Operating Cash Flow Growth AcceleratingAccelerating
Percentile Rank45
Studio
Year-over-Year Change

Year-over-year operating cash flow growth rate

Percentile
P45
Within normal range
vs 3Y Ago
-0.3x
Contraction
Streak
1 qtr
Consecutive growthAccelerating
PeriodValue
Q4 2025-28.55%
Q3 2025-82.48%
Q2 20258.28%
Q1 202515.90%
Q4 2024-47.35%
Q3 202419.19%
Q2 202428.68%
Q1 202418.81%
Q4 2023-160.20%
Q3 2023-5.48%
Q2 2023-205.11%
Q1 2023-840.91%
Q4 2022102.65%
Q3 2022-83.76%
Q2 202253.36%
Q1 2022-95.52%
Q4 2021-228.46%
Q3 2021159.47%
Q2 2021-167.55%
Q1 20210.00%
Q4 20200.00%